Vistagen announces stockholder-approved reverse stock split

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty unanimously approved by its board of directors. vistagen common stock will begin trad.
VTGN Ratings Summary
VTGN Quant Ranking